Complement and innate immune evasion strategies of the human pathogenic fungus Candida albicans

Molecular Immunology

Volumn 56, Issue 3, 2013, Pages 161-169

  Luo, Shanshan ^a,c   Skerka, Christine ^a   Kurzai, Oliver ^a   Zipfel, Peter F ^a,b  

^a HANS KNÖLL INSTITUTE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Candida albicans; Complement; Evasion strategies; Fungal infection

Indexed keywords

ANTIBODY; COMPLEMENT;

CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; ENVIRONMENTAL STRESS; FUNGAL CELL WALL; FUNGAL COLONIZATION; HOST; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; NONHUMAN; OSMOTIC PRESSURE; PRIORITY JOURNAL; REVIEW;

CANDIDA ALBICANS; COMPLEMENT; EVASION STRATEGIES; FUNGAL INFECTION;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; COMPLEMENT SYSTEM PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE;

CANDIDA; CANDIDA ALBICANS; FUNGI;

EID: 84880815437     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.05.218     Document Type: Review

References (133)

1. Agarwal V., Asmat T.M., Luo S., Jensch I., Zipfel P.F., Hammerschmidt S. Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. Journal of Biology Chemistry 2010, 285:23486-23495.
2. Alonso-Valle H., Acha O., Garcia-Palomo J.D., Farinas-Alvarez C., Fernandez-Mazarrasa C., Farinas M.C. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. European Journal of Clinical Microbiology Infection Diseases 2003, 22:254-257.
3. Arendrup M.C., Bergmann O.J., Larsson L., Nielsen H.V., Jarlov J.O., Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clinical Microbiology and Infection 2010, 16:855-862.
4. Ashman R.B., Bolitho E.M., Papadimitriou J.M. Patterns of resistance to Candida albicans in inbred mouse strains. Immunology & Cell Biology 1993, 71:221-225.
5. Ashman R.B., Papadimitriou J.M., Fulurija A., Drysdale K.E., Farah C.S., Naidoo O., Gotjamanos T. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microbial Pathogenesis 2003, 34:103-113.
6. Behnsen J., Hartmann A., Schmaler J., Gehrke A., Brakhage A.A., Zipfel P.F. The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infection and Immunity 2008, 76:820-827.
7. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
8. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: human fungal infections. Science Translational Medicine 2012, 4:165rv13.
9. Bouzani M., Ok M., McCormick A., Ebel F., Kurzai O., Morton C.O., Einsele H., Loeffler J. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. Journal of Immunology 2011, 187:1369-1376.
10. Chaffin W.L., Lopez-Ribot J.L., Casanova M., Gozalbo D., Martinez J.P. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiology and Molecular Biology Reviews 1998, 62:130-180.
11. Chai L.Y., Netea M.G., Vonk A.G., Kullberg B.J. Fungal strategies for overcoming host innate immune response. Medical Mycology 2009, 47:227-236.
12. Cheng S.C., Sprong T., Joosten L.A., van der Meer J.W., Kullberg B.J., Hube B., Schejbel L., Garred P., van Deuren M., Netea M.G. Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs. European Journal of Immunology 2012, 42:993-1004.
13. 2 sensing pathway in yeast. PLoS Pathogen 2012, 8:e1002485.
14. Crowe J.D., Sievwright I.K., Auld G.C., Moore N.R., Gow N.A., Booth N.A. Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Molecular Microbiology 2003, 47:1637-1651.
15. Cutler J.E. Chemotactic factor produced by Candida albicans. Infection and Immunity 1977, 18:568-573.
16. Cutler J.E. Defining criteria for anti-mannan antibodies to protect against candidiasis. Current Molecular Medicine 2005, 5:383-392.
17. Dalle F., Wachtler B., L'Ollivier C., Holland G., Bannert N., Wilson D., Labruere C., Bonnin A., Hube B. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cellular Microbiology 2010, 12:248-271.
18. Diamond R.D., Krzesicki R. Mechanisms of attachment of neutrophils to Candida albicans pseudohyphae in the absence of serum, and of subsequent damage to pseudohyphae by microbicidal processes of neutrophils in vitro. Journal of Clinical Investigation 1978, 61:360-369.
19. Douglas L.J. Candida biofilms and their role in infection. Trends in Microbiology 2003, 11:30-36.
20. Edens H.A., Parkos C.A., Liang T.W., Jesaitis A.J., Cutler J.E., Miettinen H.M. Non-serum-dependent chemotactic factors produced by Candida albicans stimulate chemotaxis by binding to the formyl peptide receptor on neutrophils and to an unknown receptor on macrophages. Infection and Immunity 1999, 67:1063-1071.
21. El Barkani A., Kurzai O., Fonzi W.A., Ramon A., Porta A., Frosch M., Mühlschlegel F.A. Dominant active alleles of RIM101 (PRR2) bypass the pH restriction on filamentation of Candida albicans. Molecular and Cellular Biology 2000, 20:4635-4647.
22. Falcone E.L., Holland S.M. Invasive fungal infection in chronic granulomatous disease: insights into pathogenesis and management. Current Opinion in Infectious Diseases 2012, 25:658-669.
23. Faux J.A., Agbarakwe A.E., Misbah S.A., Chapel H.M. A comparison of specific IgG antibody levels to the cell wall mannan of Candida albicans in normal individuals and in patients with primary antibody deficiency. Journal of Immunological Methods 1992, 153:167-172.
24. Ferwerda G., Netea M.G., Joosten L.A., van der Meer J.W., Romani L., Kullberg B.J. The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine 2010, 28:614-622.
25. Filler S.G., Sheppard D.C. Fungal invasion of normally non-phagocytic host cells. PLoS Pathogens 2006, 2:e129.
26. Fradin C., De G.P., MacCallum D., Schaller M., Klis F., Odds F.C., Hube B. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Molecular Microbiology 2005, 56:397-415.
27. Fuchs T.A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., Weinrauch Y., Brinkmann V., Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. Journal of Cell Biology 2007, 176:231-241.
28. Gantner B.N., Simmons R.M., Underhill D.M. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO Journal 2005, 24:1277-1286.
29. Geiger J., Wessels D., Lockhart S.R., Soll D.R. Release of a potent polymorphonuclear leukocyte chemoattractant is regulated by white-opaque switching in Candida albicans. Infection and Immunity 2004, 72:667-677.
30. Gelfand J.A., Hurley D.L., Fauci A.S., Frank M.M. Role of complement in host defense against experimental disseminated candidiasis. Journal of Infectious Diseases 1978, 138:9-16.
31. Gow N.A., Hube B. Importance of the Candida albicans cell wall during commensalism and infection. Current Opinion in Microbiology 2012, 15:406-412.
32. Greenfield R.A., Stephens J.L., Bussey M.J., Jones J.M. Quantitation of antibody to Candida mannan by enzyme-linked immunosorbent assay. Journal of Laboratory and Clinical Medicine 1983, 101:758-771.
33. Gropp K., Schild L., Schindler S., Hube B., Zipfel P.F., Skerka C. The yeast Candida albicans evades human complement attack by secretion of aspartic proteases. Molecular Immunology 2009, 47:465-475.
34. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., Herwaldt L., Pfaller M., Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clinical Infectious Diseases 2003, 37:1172-1177.
35. Han Y., Cutler J.E. Antibody response that protects against disseminated candidiasis. Infection and Immunity 1995, 63:2714-2719.
36. Han Y., Ulrich M.A., Cutler J.E. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. Journal of Infectious Diseases 1999, 179:1477-1484.
37. Han Y., Kozel T.R., Zhang M.X., MacGill R.S., Carroll M.C., Cutler J.E. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. Journal of Immunology 2001, 167:1550-1557.
38. Han Y., Rhew K.Y. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis. Archives of Pharmacal Research 2012, 35:2021-2027.
39. Heinsbroek S.E., Brown G.D., Gordon S. Dectin-1 escape by fungal dimorphism. Trends in Immunology 2005, 26:352-354.
40. Heinz W.J., Kurzai O., Brakhage A.A., Fonzi W.A., Korting H.C., Frosch M., Mühlschlegel F.A. Molecular responses to changes in the environmental pH are conserved between the fungal pathogens Candida dubliniensis and Candida albicans. International Journal of Medical Microbiology 2000, 290:231-238.
41. Hernández-Santos N., Gaffen S.L. Th17 cells in immunity to Candida albicans. Cell Host & Microbe 2012, 11:425-435.
42. Hornbach A., Heyken A., Schild L., Hube B., Löffler J., Kurzai O. The glycosylphosphatidylinositol-anchored protease Sap9 modulates the interaction of Candida albicans with human neutrophils. Infection and Immunity 2009, 77:5216-5224.
43. Hostetter M.K. Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces. Clinical Microbiology Reviews 1994, 7:29-42.
44. Hube B. Infection-associated genes of Candida albicans. Future Microbiology 2006, 1:209-218.
45. Jacobsen I.D., Wilson D., Wächtler B., Brunke S., Naglik J.R., Hube B. Candida albicans dimorphism as a therapeutic target. Expert Review of Anti-infective Therapy 2012, 10:85-93.
46. Jakab E., Paulsson M., Ascencio F., Ljungh A. Expression of vitronectin and fibronectin binding by Candida albicans yeast cells. APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica 1993, 101:187-193.
47. Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology 2001, Garland Publishing, New York and London.
48. 2 is a leukocyte receptor for Candida albicans and is essential for protection against fungal infections. Journal Immunology 2012, 189:2468-2477.
49. Jones J.M. Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infection and Immunity 1980, 30:78-89.
50. Kapetanovic R., Cavaillon J.M. Early events in innate immunity in the recognition of microbial pathogens. Expert Opinion on Biological Therapy 2007, 7:907-918.
51. Kirkpatrick C.J., Wagner M., Hermanns I., Klein C.L., Kohler H., Otto M., van Kooten T.G., Bittinger F. Physiology and cell biology of the endothelium: a dynamic interface for cell communication. International Journal of Microcirculation 1997, 17:231-240.
52. Kobayashi S.D., Voyich J.M., Burlak C., DeLeo F.R. Neutrophils in the innate immune response. Archivum Immunologiae et Therapia Experimentalis 2005, 53:505-517.
53. Koh A.Y., Köhler J.R., Coggshall K.T., Van Rooijen N., Pier G.B. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathogens 2008, 4:e35.
54. Kozel T.R., Pfrommer G.S., Redelman D. Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clinical & Experimental Immunology 1987, 70:238-246.
55. Kozel T.R., Weinhold L.C., Lupan D.M. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infection and Immunity 1996, 64:3360-3368.
56. Kozel T.R. Activation of the complement system by pathogenic fungi. Clinical Microbiology Reviews 1996, 9:34-46.
57. Kozel T.R., MacGill R.S., Percival A., Zhou Q. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infection and Immunity 2004, 72:209-218.
58. Kurzai O., Korting H.C., Harmsen D., Bautsch W., Molitor M., Frosch M., Mühlschlegel F.A. Molecular and phenotypic identification of the yeast pathogen Candida dubliniensis. Journal of Molecular Medicine 2000, 78:521-529.
59. Kurzai O., Schmitt C., Bröcker E., Frosch M., Kolb-Mäurer A. Polymorphism of Candida albicans is a major factor in the interaction with human dendritic cells International. Journal of Medical Microbiology 2005, 295:121-127.
60. Laursen N.S., Magnani F., Gottfredsen R.H., Petersen S.V., Andersen G.R. Structure, function and control of complement C5 and its proteolytic fragments. Current Molecular Medicine 2012, 12:1083-1097.
61. Lehmann P.F., Reiss E. Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia 1980, 70:89-93.
62. Leroy O., Gangneux J.P., Montravers P., Mira J.P., Gouin F., Sollet J.P., Carlet J., Reynes J., Rosenheim M., Regnier B., Lortholary O. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Critical Care Medicine 2009, 37:1612-1618.
63. Lesiak-Markowicz I., Vogl G., Schwarzmuller T., Speth C., Lass-Florl C., Dierich M.P., Kuchler K., Wurzner R. Candida albicans Hgt1p, a multifunctional evasion molecule: complement inhibitor, CR3 analogue, and human immunodeficiency virus-binding molecule,. Journal of Infectious Diseases 2011, 204:802-809.
64. Limper A.H., Standing J.E. Vitronectin interacts with Candida albicans and augments organism attachment to the NR8383 macrophage cell line. Immunology Letters 1994, 42:139-144.
65. Lorenz M.C., Bender J.A., Fink G.R. Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryotic Cell 2004, 3:1076-1087.
66. Lukasser-Vogl E., Gruber A., Lass-Flörl C., Eder A., Høgåsen A.K., Morgan B.P., Dierich M.P., Würzner R. Membrane attack complex formation on yeast as trigger of selective release of terminal complement proteins from human polymorphonuclear leukocytes. FEMS Immunology & Medical Microbiology 2000, 28:15-23.
67. Luo S., Hoffmann R., Skerka C., Zipfel P.F. Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-, factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. Journal of Infectious Diseases 2013, 207:594-603.
68. Luo S., Blom A.M., Rupp S., Hippler U.C., Hube B., Skerka C., Zipfel P.F. The pH regulated antigen 1 of Candida albicans binds the human complement inhibitor C4b-binding protein and mediates fungal complement evasion. Journal of Biological Chemistry 2011, 286:8021-8029.
69. Luo S., Hartmann A., Dahse H.M., Skerka C., Zipfel P.F. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3. Journal of Immunology 2010, 185:2164-2173.
70. Luo S., Poltermann S., Kunert A., Rupp S., Zipfel P.F. Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, FHL-1 and plasminogen binding surface protein. Molecular Immunology 2009, 47:541-550.
71. Maródi L., Korchak H.M., Johnston R.B. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. Journal of Immunology 1991, 146:2783-2789.
72. Martin R., Moran G.P., Jacobsen I.D., Heyken A., Domey J., Sullivan D.J., Kurzai O., Hube B. The Candida albicans-specific gene EED1 encodes a key regulator of hyphal extension. PLoS ONE 2011, 6:e18394.
73. Martin R., Albrecht-Eckardt D., Brunke S., Hube B., Hünniger K., Kurzai O. A core filamentation response network in Candida albicans is restricted to eight genes. PLoS ONE 2013, 8:e58613.
74. McKenzie S.E., Schreiber A.D. Fc gamma receptors in phagocytes. Current Opinion in Hematology 1998, 5:16-21.
75. Medzhitov R., Janeway C. Innate immune recognition: mechanisms and pathways. Immunological Reviews 2000, 173:89-97.
76. Medzhitov R., Janeway C. Innate immunity. New England Journal of Medicine 2000, 343:338-344.
77. Meiller T.F., Hube B., Schild L., Shirtliff M.E., Scheper M.A., Winkler R., Ton A., Jabra-Rizk M.A. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS ONE 2009, 4:e5039.
78. Meri T., Blom A.M., Hartmann A., Lenk D., Meri S., Zipfel P.F. The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infection and Immunity 2004, 72:6633-6641.
79. Meri T., Hartmann A., Lenk D., Eck R., Würzner R., Hellwage J., Meri S., Zipfel P.F. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infection and Immunity 2002, 70:5185-5192.
80. Mikes P.S., Polomski L.L., De Musis M.R., Gee J.B. The neutrophil, friend or foe: pharmacologic manipulation. Respiration 1988, 54:9-15.
81. Miramón P., Dunker C., Windecker H., Bohovych I.M., Brown A.J., Kurzai O., Hube B. Cellular responses of Candida albicans to phagocytosis and the extracellular activities of neutrophils are critical to counteract carbohydrate starvation, oxidative and nitrosative stress. PLoS ONE 2012, 7:e52850.
82. Moore K.W., O'Garra A., de Waal W.J., Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annual Review of Immunology 1993, 11:165-190.
83. Mullick A., Elias M., Picard S., Bourget L., Jovcevski O., Gauthier S., Tuite A., Harakidas P., Bihun C., Massie B., Gros P. Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infection and Immunity 2004, 72:5868-5876.
84. Mullick A., Leon Z., Min-Oo G., Berghout J., Lo R., Daniels E., Gros P. Cardiac failure in C5-deficient A/J mice after Candida albicans infection. Infection and Immunity 2006, 74:4439-4451.
85. Nagpal R., Patel A., Gibson M.C. Epithelial topology. BioEssays 2008, 30:260-266.
86. Netea M.G., Sutmuller R., Hermann C., Van der Graaf C.A., Van der Meer J.W., van Krieken J.H., Hartung T., Adema G., Kullberg B.J. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. Journal of Immunology 2004, 172:3712-3718.
87. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., Kauffman C.A., Hyslop N., Mangino J.E., Chapman S., Horowitz H.W., Edwards J.E., Dismukes W.E. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clinical Infectious Diseases 2003, 37:634-643.
88. Park H., Myers C.L., Sheppard D.C., Phan Q.T., Sanchez A.A., Je E., Filler S.G. Role of the fungal Ras-protein kinase A pathway in governing epithelial cell interactions during oropharyngeal candidiasis. Cellular Microbiology 2005, 7:499-510.
89. Phan Q.T., Myers C.L., Fu Y., Sheppard D.C., Yeaman M.R., Welch W.H., Ibrahim A.S., Edwards J.E., Filler S.G. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biology 2007, 5:e64.
90. Poltermann S., Kunert A., von der Heide M., Eck R., Hartmann A., Zipfel P.F. Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. Journal of Biological Chemistry 2007, 282:37537-37544.
91. Quinn M.T., Gauss K.A. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. Journal of Leukocyte Biology 2004, 76:760-781.
92. Radovanovic I., Mullick A., Gros P. Genetic control of susceptibility to infection with Candida albicans in mice. PLoS ONE 2011, 6:e18957.
93. Re F., Strominger J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. Journal of Biological Chemistry 2001, 276:37692-37699.
94. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Current Opinion in Microbiology 1999, 2:363-367.
95. Rubin-Bejerano I., Abeijon C., Magnelli P., Grisafi P., Fink G.R. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host & Microbe 2007, 2:55-67.
96. Ruhnke M., Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer-review of the literature. European Journal of Medical Research 2002, 7:227-235.
97. Saunus J.M., Kazoullis A., Farah C.S. Cellular and molecular mechanisms of resistance to oral Candida albicans infections. Frontiers in Bioscience 2008, 13:5345-5358.
98. Schaller M., Borelli C., Korting H.C., Hube B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005, 48:365-377.
99. Segal A.W. How neutrophils kill microbes. Annual Review of Immunology 2005, 23:197-223.
100. Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R., Dower S.K., Cosman D., Goodwin R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990, 248:1019-1023.
101. Smith C.A., Hu F.Q., Smith T.D., Richards C.L., Smolak P., Goodwin R.G., Pickup D.J. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB that binds TNF but not LT alpha. Virology 1996, 223:132-147.
102. Soloviev D.A., Fonzi W.A., Sentandreu R., Pluskota E., Forsyth C.B., Yadav S., Plow E.F. Identification of pH-regulated antigen 1 released from Candida albicans as the major ligand for leukocyte integrin alphaMbeta2. Journal of Immunology 2007, 178:2038-2046.
103. Sonesson A., Ringstad L., Nordahl E.A., Malmsten M., Mörgelin M., Schmidtchen A. Antifungal activity of C3a and C3a-derived peptides against Candida. Biochimica et Biophysica Acta 2007, 1768:346-353.
104. Spellberg B.J., Ibrahim A.S., Avanesian V., Fu Y., Myers C., Phan Q.T., Filler S.G., Yeaman M.R., Edwards J.E. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. Journal of Infectious Diseases 2006, 194:256-260.
105. Spellberg B., Ibrahim A.S., Lin L., Avanesian V., Fu Y., Lipke P., Otoo H., Ho T., Edwards J.E. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. Journal of Infectious Diseases 2008, 197:967-971.
106. Spreghini E., Gismondi A., Piccoli M., Santoni G. Evidence for alphavbeta3 and alphavbeta5 integrin-like vitronectin (VN) receptors in Candida albicans and their involvement in yeast cell adhesion to VN. Journal of Infectious Diseases 1999, 180:156-166.
107. Staab J.F., Bradway S.D., Fidel P.L., Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 1999, 283:1535-1538.
108. Staab J.F., Sundstrom P. Genetic organization and sequence analysis of the hypha-specific cell wall protein gene HWP1 of Candida albicans. Yeast 1998, 14:681-686.
109. Sudbery P.E. Growth of Candida albicans hyphae. Nature Reviews Microbiology 2011, 9(10):737-748.
110. Sundstrom P. Adhesins in Candida albicans. Current Opinion in Microbiology 1999, 2:353-357.
111. Triebel T., Grillhösl B., Kacani L., Lell C.P., Fuchs A., Speth C., Lass-Flörl C., Steinmann J., Dierich M.P., Würzner R. Importance of the terminal complement components for immune defence against Candida. International Journal of Medical Microbiology 2003, 292:527-536.
112. Tsoni S.V., Kerrigan A.M., Marakalala M.J., Srinivasan N., Duffield M., Taylor P.R., Botto M., Steele C., Brown G.D. Complement C3 plays an essential role in the control of opportunistic fungal infections. Infection and Immunity 2009, 77:3679-3685.
113. Tuite A., Mullick A., Gros P. Genetic analysis of innate immunity in resistance to Candida albicans. Genes & Immunity 2004, 5:576-587.
114. Tuomanen E. Entry of pathogens into the central nervous system. FEMS Microbiology Reviews 1996, 18:289-299.
115. Ullmann B.D., Myers H., Chiranand W., Lazzell A.L., Zhao Q., Vega L.A., Lopez-Ribot J.L., Gardner P.R., Gustin M.C. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryotic Cell 2004, 3:715-723.
116. Urban C.F., Reichard U., Brinkmann V., Zychlinsky A. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cellular Microbiology 2006, 8:668-676.
117. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunological Reviews 2007, 218:178-196.
118. Vonk A.G., Netea M.G., van der Meer J.W., Kullberg B.J. Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy. Expert Opinion on Biological Therapy 2006, 6:891-903.
119. Wellington M., Dolan K., Krysan D.J. Live Candida albicans suppresses production of reactive oxygen species in phagocytes. Infection and Immunity 2009, 77:405-413.
120. Wen L., Atkinson J.P., Giclas P.C. Clinical and laboratory evaluation of complement deficiency. Journal of Allergy and Clinical Immunology 2004, 113:585-593.
121. Wetsel R.A., Fleischer D.T., Haviland D.L. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. Journal of Biological Chemistry 1990, 265:2435-2440.
122. Wilson D., Hube B. Hgc1 mediates dynamic Candida albicans-endothelium adhesion events during circulation. Eukaryotic Cell 2010, 9:278-287.
123. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., Malech H.L., Holland S.M., Ochs H., Quie P., Buckley R.H., Foster C.B., Chanock S.J., Dickler H. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79:155-169.
124. Wozniok I., Hornbach A., Schmitt C., Frosch M., Einsele H., Hube B., Löffler J., Kurzai O. Induction of ERK-kinase signalling triggers morphotype-specific killing of Candida albicans filaments by human neutrophils. Cellular Microbiology 2008, 10:807-820.
125. Zakikhany K., Naglik J.R., Schmidt-Westhausen A., Holland G., Schaller M., Hube B. In vivo transcript profiling of Candida albicans identifies a gene essential for interepithelial dissemination. Cellular Microbiology 2007, 9:2938-2954.
126. Zakikhany K., Thewes S., Wilson D., Martin R., Albrecht A., Hube B. From attachment to invasion: infection associated genes of Candida albicans. Nippon Ishinkin Gakkai Zasshi 2008, 49:245-251.
127. Zhang M.X., Lupan D.M., Kozel T.R. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infection and Immunity 1997, 65:3822-3827.
128. Zhang M.X., Kozel T.R. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infection and Immunity 1998, 66:4845-4850.
129. Zipfel P.F., Hallström T., Hammerschmidt S., Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 2008, 26:I67-I174.
130. Zipfel P.F., Jokiranta T.S., Hellwage J., Koistinen V., Meri S. The factor H protein family. International Immunopharmacology 1999, 42:53-60.
131. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nature Reviews Immunology 2009, 9:729-740.
132. Zipfel P.F., Skerka C. Complement, Candida, and cytokines: the role of C5a in host response to fungi. European Journal of Immunology 2012, 42:822-825.
133. Zipfel P.F., Würzner R., Skerka C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Molecular Immunology 2007, 44:3850-3857.